U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H23FN2O2.ClH.2H2O
Molecular Weight 438.92
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROLUPERIDONE HYDROCHLORIDE

SMILES

O.O.Cl.FC1=CC=C(C=C1)C(=O)CN2CCC(CN3CC4=C(C=CC=C4)C3=O)CC2

InChI

InChIKey=NZKANSJXJCILHS-UHFFFAOYSA-N
InChI=1S/C22H23FN2O2.ClH.2H2O/c23-19-7-5-17(6-8-19)21(26)15-24-11-9-16(10-12-24)13-25-14-18-3-1-2-4-20(18)22(25)27;;;/h1-8,16H,9-15H2;1H;2*1H2

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H23FN2O2
Molecular Weight 366.4286
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
7.53 nM [Ki]
Target ID: Q5BJF2
Gene ID: 27346.0
Gene Symbol: TMEM97
Target Organism: Homo sapiens (Human)
8.19 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
2017 Dec 1
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group.
After at least 5 days' withdrawal from all antipsychotic medication, Schizophrenia patients were randomly assigned to receive 32 mg/day or 64 mg/day of oral CYR-101 (MIN-101) for 12 weeks.
Route of Administration: Oral
CYR-101 (MIN-101) has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:15 GMT 2023
Edited
by admin
on Fri Dec 15 15:30:15 GMT 2023
Record UNII
WFL7TF8DTP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROLUPERIDONE HYDROCHLORIDE
USAN  
Official Name English
1H-ISOINDOL-1-ONE, 2-((1-(2-(4-FLUOROPHENYL)-2-OXOETHYL)-4-PIPERIDINYL)METHYL)-2,3-DIHYDRO-, HYDROCHLORIDE, HYDRATE (1:1:2)
Systematic Name English
2-({1-[2-(4-Fluorophenyl)-2-oxoethyl]piperidin-4-yl}methyl)-2,3-dihydro-1H-isoindol-1-one monohydrochloride dihydrate
Systematic Name English
ROLUPERIDONE HYDROCHLORIDE [USAN]
Common Name English
CYR-101 HYDROCHLORIDE DIHYDRATE
Code English
MT-210
Code English
MIN-101
Code English
Code System Code Type Description
DRUG BANK
DBSALT002798
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
PUBCHEM
21078080
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
CAS
1937215-88-7
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
SMS_ID
100000178096
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
FDA UNII
WFL7TF8DTP
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
EVMPD
SUB193660
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
NCI_THESAURUS
C170371
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
USAN
EF-68
Created by admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY